| Literature DB >> 28666740 |
Renata A G Reis1, Felipe Antunes Calil2, Patricia Rosa Feliciano3, Matheus Pinto Pinheiro4, M Cristina Nonato5.
Abstract
The flavoenzyme dihydroorotate dehydrogenase catalyzes the stereoselective oxidation of (S)-dihydroorotate to orotate in the fourth of the six conserved enzymatic reactions involved in the de novo pyrimidine biosynthetic pathway. Inhibition of pyrimidine metabolism by selectively targeting DHODHs has been exploited in the development of new therapies against cancer, immunological disorders, bacterial and viral infections, and parasitic diseases. Through a chronological narrative, this review summarizes the efforts of the scientific community to achieve our current understanding of structural and biochemical properties of DHODHs. It also attempts to describe the latest advances in medicinal chemistry for therapeutic development based on the selective inhibition of DHODH, including an overview of the experimental techniques used for ligand screening during the process of drug discovery.Entities:
Keywords: Dihydroorotate dehydrogenase; Drug target; Flavoenzyme; Pyrimidine biosynthesis
Mesh:
Substances:
Year: 2017 PMID: 28666740 DOI: 10.1016/j.abb.2017.06.019
Source DB: PubMed Journal: Arch Biochem Biophys ISSN: 0003-9861 Impact factor: 4.013